Under the direction of GIOSTAR Co-Founder Dr. Anand Srivastava, a patient was treated with a topical application of mesenchymal stem cells. Remarkably, the patient saw their psoriasis regress completely after only one month.
Tag: dr anand srivastava
Editorial: Mesenchymal stem cells may be a credible alternative therapy to fight with COVID-19 pandemic
Drs. Anand Srivastava and Prabhat Soni write in a medical journal on the potential benefits of stem cells in fighting against COVID-19. GIOSTAR recently received FDA Approval Under Compassionate Use to treat COVID-19 patients under compassionate use.
For more than two decades, Dr. Anand Srivastava and GIOSTAR have been at the forefront of stem cell therapy and research. The company is currently in process of FDA approval for groundbreaking clinical trials regarding Type 2 Diabetes, which impacts roughly 1 in 10 Americans.
Under the direction of Dr. Srivastava, the patient was treated with Mesenchymal Stem Cell Conditioned Media (MSC-CM), which was applied topically to affected areas daily. Remarkably, after only one month, the patient saw their psoriasis regress completely.
Dr. Gellis continues his insightful discussion with Dr. Anand Srivastava about the ever-evolving landscape of regenerative medicine.
This installment of GIOTalk features a helpful overview of Dr. Anand Srivastava’s ground-breaking discoveries in the field of stem cell research, along with his views on the future of regenerative medicine.